- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01216657
Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma
An Open-label, Uncontrolled Phase II Trial of Single Agent Sunitinib (SU 11248) for Patients With Chemo-refractory Metastatic Melanoma
Studieoversigt
Detaljeret beskrivelse
This is a single agent 2-step phase 2 study with a one-year follow-up to evaluate the antitumor activity of Sunitinib administered in treatment cycles of 6 weeks duration (4 weeks treatment and 2 weeks rest) in patients with chemo-refractory melanoma. If the first step shows sufficient efficacy and tolerability the study will continue to step 2. Treatment will continue for 9 months or until disease progression or until intolerable adverse events occur. Subsequently the patients will be followed up for 1 year. Tumor assessment will be performed at baseline, at the end of cycle 1,2,3 and subsequently at the end of every uneven cycle (5,7,9,…).
A total of 40 patients will be enrolled in this trial.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Frankfurt/Main, Tyskland, 60488
- Krankenhaus Nordwest
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male and female patients aged 18 years and older.
- Diagnosis of unresectable (Stage III) or metastatic (Stage IV), histologically or cytologically proven, melanoma without clinically meaningful surgical or radiotherapeutical options except for mucosal or ocular origin of the primary tumor.
- Subjects must have completed a first or second line chemotherapy or be progressed under chemotherapeutic treatment. The previous treatment must have included DTIC alone or in combination
- Performance status of 0 to 2 on the ECOG scale
- Life expectancy > 12 weeks.
- Patients must be able to swallow Sunitinib capsules.
- Evidence of measurable disease according to the RECIST criteria
- Prior radiation therapy allowed if completed at least 2 weeks and any major surgery allowed if completed at least 4 weeks prior to first dose of Sunitinib.
- Resolution of all acute toxic side effects of prior therapy or surgical procedures to grade < 1 NCI-CTC (except for laboratory values).
Adequate organ function including the following:
- platelets > 100 x 109/L
- hemoglobin > 8 g/dl
- absolute neutrophils count (AGC) > 1.5 x 109/L.
Hepatic:
- bilirubin <=1.5 times upper limit of normal (ULN)
- aspartate transaminase (AST) and alanine transaminase (ALT) <=2.5 times normal (AST and ALT <=5.0 times normal is acceptable if liver function abnormalities are due to underlying malignancy).
- INR < 1.5 or a PTT within normal limits.
- Subjects must not have any evidence of a bleeding diathesis.
Renal:
- Serum creatinine < 1.5 x ULN
- serum calcium < 1.2 mg/dl.
- Pancreatic:
- Serum lipase and amylase within normal range.
- Signed and dated informed consent
Exclusion Criteria:
- Prior treatment with ras-raf-MEK-ERK signaling pathway inhibitors (including trastuzumab, sorafenib, farnesyl transferase inhibitors or MEK inhibitors), or treatment with drugs which target VEGF (such as bevacizumab).
- Radiotherapy, except palliative radiotherapy during study participation as described.
- Known active infection (i.e. HIV, chronic hepatitis B or C, at the discretion of the investigator)
- History of organ allograft or stem cell transplantation.
- Coexisting second malignancy (excluding basal or squamous cell carcinoma of the skin, superficial bladder cancer and in situ carcinoma of the cervix with no evidence of recurrence) or history of prior malignancy
- Bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection (> hemicolectomie or extensive small intestine resection with chronic diarrhea), Crohn's disease, ulcerative colitis.
- Current history of chronic diarrhea defined as persisting diarrhea for more than 3 weeks at study entry due to any reason.
Any of the following events prior to starting the trial treatment: *clinically evident congestive heart failure, as defined by New York Health Association (NYHA) > class II
- Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2
- Atrial fibrillation of any grade, or prolongation of the QTc interval to >450 msec for males or >470 msec for females.
- Subjects on beta-blockers and digoxin must be monitored closely
- QT-interval > 450 msec
- Risk factors for torsade-de-pointes-tachycardia (i.e.. Hypokalaemia, congenital Long-QT-syndrome)
- Active coronary artery disease or ischemia (myocardial infarction within the last 6 months prior to study entry)
- Coronary/peripheral artery bypass graft
- Cerebrovascular accident or transient ischemic attack
- Active disseminated intravascular coagulation, or history of clinically significant bleeding within the past 6 months, including gross hemoptysis or haematuria, or underlying coagulopathy
- Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therapy).
- Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with trial participation or trial drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into the trial.
- Participation in any other clinical trial within the last 3 weeks.
- Pregnant or lactating women.
- Known allergic/hypersensitivity reaction to any of the components of the treatment, or known drug abuse/alcohol abuse.
- Active CNS metastatic or meningeal tumors.
- Patients with seizure disorders requiring medication (such as antiepileptics, the use of carbamazepine, phenytion an phenobarbital is prohibited).
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: sunitinib
50 mg Sunitinib daily for 4 weeks, then 2 weeks without treatment
|
50 mg oral, daily, for 4 weeks, then 2 weeks without treatment, repeat at d43
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
clinical benefit rate cycle 1-3
Tidsramme: tumor assessment every 6 weeks
|
clinical benefit rate defined as a CR + PR + SD > 4 months duration
|
tumor assessment every 6 weeks
|
clinical benefit rate cycle 4 and more
Tidsramme: tumor assessment every 12 weeks
|
clinical benefit rate defined as a CR + PR + SD > 4 months duration
|
tumor assessment every 12 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
response rate cycle 1-3
Tidsramme: tumor assessment every 6 weeks
|
response rate defined as CR+PR
|
tumor assessment every 6 weeks
|
progression free survival
Tidsramme: follow-up one year
|
follow-up one year
|
|
overall survival
Tidsramme: follow-up for one year
|
follow-up for one year
|
|
response rate cycle 4 and more
Tidsramme: every 12 weeks
|
response rate defined as CR+PR
|
every 12 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Elke Jäger, Prof. Dr., Krankenhaus Nordwest
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter histologisk type
- Neoplasmer
- Neuroektodermale tumorer
- Neoplasmer, kimceller og embryonale
- Neoplasmer, nervevæv
- Neuroendokrine tumorer
- Nevi og melanomer
- Melanom
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Enzymhæmmere
- Antineoplastiske midler
- Angiogenese-hæmmere
- Angiogenesemodulerende midler
- Vækststoffer
- Væksthæmmere
- Proteinkinasehæmmere
- Sunitinib
Andre undersøgelses-id-numre
- S379 SUMA
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Chemo-refractory Melanoma
-
National Cancer Institute (NCI)ExelisisAfsluttetStage IV Uveal Melanoma AJCC v7 | Tilbagevendende uveal melanom | Stage III Uveal Melanoma AJCC v7 | Stage IIIA Uveal Melanoma AJCC v7 | Stadie IIIB Uveal Melanoma AJCC v7 | Stage IIIC Uveal Melanoma AJCC v7Forenede Stater, Canada
-
Nantes University HospitalTrukket tilbageCD22+ Relapsed/Refractory B-ALLFrankrig
-
European Society for Blood and Marrow TransplantationMallinckrodtAfsluttetSteroid Refractory GVHDSpanien, Det Forenede Kongerige, Sverige, Italien, Israel, Frankrig, Danmark, Tyskland, Polen, Kalkun, Rumænien, Belgien, Grækenland, Den Russiske Føderation
-
Samsung Medical CenterAfsluttetHER2-positiv Refractory Advanced CancerKorea, Republikken
-
National Cancer Institute (NCI)AfsluttetFase IV kutan melanom AJCC v6 og v7 | Tilbagevendende melanom | Fase IIIC kutan melanom AJCC v7 | Slimhinde melanom | Iris melanom | Fase IIIA kutan melanom AJCC v7 | Fase IIIB kutan melanom AJCC v7 | Stage IV Uveal Melanoma AJCC v7 | Medium/Large Size Posterior Uveal Melanom | Tilbagevendende uveal melanom | Stage IIIA Uveal Melanoma AJCC v7 og andre forholdForenede Stater
-
Shanghai Pudong HospitalUTC Therapeutics Inc.Trukket tilbageMesothelin-positive Advanced Refractory Solid TumorsKina
-
Agenus Inc.AfsluttetAvancerede solide kræftformer | Advanced Solid Cancers Refractory to PD-1Forenede Stater
-
ElsaLys BiotechIkke rekrutterer endnu
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)AfsluttetFase IV kutan melanom AJCC v6 og v7 | Okulært melanom | Fase IIIC kutan melanom AJCC v7 | Kutant melanom | Slimhinde melanom | Fase IIIB kutan melanom AJCC v7 | Stage IV Uveal Melanoma AJCC v7 | Stadie IIIB Uveal Melanoma AJCC v7 | Stage IIIC Uveal Melanoma AJCC v7 | Stadie III Akral Lentiginøst Melanom AJCC... og andre forholdForenede Stater
-
Sidney Kimmel Cancer Center at Thomas Jefferson...PfizerAktiv, ikke rekrutterendeCiliær krop og choroid melanom, medium/stor størrelse | Ciliær krop og choroidea melanom, lille størrelse | Iris melanom | Stadium IIIA Intraokulært melanom | Stadium IIIB Intraokulært melanom | Stadie IIIC Intraokulært melanom | Stadie I Intraokulært melanom | Stadie IIA Intraokulært melanom | Stadie IIB... og andre forholdForenede Stater
Kliniske forsøg med Sunitinib
-
AGO Study GroupPhilipps University Marburg Medical Center; HSK Reasearch GmbH WiesbadenAfsluttetPlatin refraktær epitelial ovariecancer | Primær kræft i bughinden | Kræft i æggelederenTyskland
-
Cogent Biosciences, Inc.RekrutteringMetastatisk kræft | Avancerede gastrointestinale stromale tumorerForenede Stater, Korea, Republikken, Spanien, Det Forenede Kongerige, Australien, Frankrig, Italien, Holland, Taiwan, Tyskland, Danmark, Hong Kong, Canada, Sverige, Norge, Mexico, Tjekkiet, Argentina, Ungarn, Brasilien, Chile, Polen
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)AfsluttetNyrekræftForenede Stater
-
PfizerAfsluttetBrystneoplasmerForenede Stater
-
National Cancer Institute (NCI)AfsluttetStadie I Myelom | Stadie II Myelom | Stadium III Myelom | Refraktær MyelomForenede Stater
-
PfizerAfsluttetGastrointestinale stromale tumorerKorea, Republikken
-
California Pacific Medical Center Research InstitutePfizer; University of California, San FranciscoAfsluttet
-
National Cancer Institute (NCI)AfsluttetStadie IV Ovarieepitelkræft | Tilbagevendende ovarieepitelkræft | Tilbagevendende primær peritonealhulekræft | Fase IV Primær peritonealhulekræft | Tilbagevendende æggelederkræft | Stadie IIIA Æggelederkræft | Stadie IIIB Æggelederkræft | Stadie IIIC Æggelederkræft | Stadie IV Æggelederkræft | Stadie IIIA... og andre forholdCanada
-
Asan Medical CenterAfsluttetMetastatisk nyrecellekarcinomKorea, Republikken
-
National Cancer Institute (NCI)AfsluttetMyelodysplastiske syndromer | Kronisk myelomonocytisk leukæmi | Sekundære myelodysplastiske syndromer | de Novo Myelodysplastiske SyndromerCanada, Forenede Stater